U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354711) titled 'A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors' on Jan. 13.
Brief Summary: The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
Study Start Date: Jan. 04
Study Type: INTERVENTIONAL
Condition:
Lung Cancer
Stomach Cancer
Intervention:
DRUG: 3H-10000
3H-10000 will be administered by infusion Q2W in 28-day cycles.
Recruitment Status: RECRUITING
Sponsor: 3H Pharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Healt...